Ellen Aurlien
Position: PhD, MD
Phone: +47 22 93 40 00
Email:
 

Author network for Ellen Aurlien by COREMINE medical


Publications 2014

Kolstad A, Kumari S, Walczak M, Madsbu U, Hagtvedt T, Bogsrud TV, Kvalheim G, Holte H, Aurlien E, Delabie J, Tierens A, Olweus J (2014)
Sequential intranodal immunotherapy induces antitumor immunity and correlated regression of disseminated follicular lymphoma
Blood, 125 (1), 82-9
PubMed 25293773

Publications 2013

Bersvendsen H, Kolstad A, Blystad AK, Aurlien E, Fosså A, Kvaløy SO, Holte H, Lauritzsen GF (2013)
Multimodal treatment with ALL-like chemotherapy, Auto-SCT and radiotherapy for lymphoblastic lymphoma
Acta Oncol, 53 (5), 680-7
PubMed 24237392

Publications 2012

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A (2012)
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant, 47 (12), 1552-7
PubMed 22522568

Publications 2011

Fosså A, Fiskvik IH, Kolstad A, Lauritzsen GF, Aurlien E, Blystad AK, Hole KH, Ikonomou IM, Holte H (2011)
Two escalated followed by six standard BEACOPP in advanced-stage high-risk classical Hodgkin lymphoma: high cure rates but increased risk of aseptic osteonecrosis
Ann Oncol, 23 (5), 1254-9
PubMed 21926399

Publications 2007

Kvinnsland Y, Stokke T, Aurlien E (2007)
Log normal distribution of cellular uptake of radioactivity
J Nucl Med, 48 (2), 327; author reply 327-8
PubMed 17268032

Publications 2002

Aurlien E, Kvinnsland Y, Larsen RH, Bruland ØS (2002)
Radiation doses to non-Hodgkin's lymphoma cells and normal bone marrow exposed in vitro. Comparison of an alpha-emitting radioimmunoconjugate and external gamma-irradiation
Int J Radiat Biol, 78 (2), 133-42
PubMed 11779363

Publications 2001

Aurlien E, Holte H, Kvaloy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
Eur. J. Haematol., 66 64, 14-20

Aurlien E, Holte H, Kvaløy S, Jakobsen E, Rusten LS, Kvalheim G (2001)
Combination chemotherapy containing mitoguazone, ifosfamide, methotrexate, etoposide (MIME) and G-CSF efficiently mobilize peripheral blood progenitor cells in heavily pre-treated relapsed lymphoma patients
Eur J Haematol Suppl, 64, 14-20
PubMed 11486395

Kvinnsland Y, Stokke T, Aurlien E (2001)
Radioimmunotherapy with alpha-particle emitters: microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei
Radiat Res, 155 (2), 288-96
PubMed 11175663

Publications 2000

Aurlien E, Larsen RH, Akabani G, Olsen DR, Zalutsky MR, Bruland OS (2000)
Exposure of human osteosarcoma and bone marrow cells to tumour-targeted alpha-particles and gamma-irradiation: analysis of cell survival and microdosimetry
Int J Radiat Biol, 76 (8), 1129-41
PubMed 10947126

Aurlien E, Larsen RH, Kvalheim G, Bruland OS (2000)
Demonstration of highly specific toxicity of the alpha-emitting radioimmunoconjugate(211)At-rituximab against non-Hodgkin's lymphoma cells
Br J Cancer, 83 (10), 1375-9
PubMed 11044364

Publications 1998

Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G (1998)
Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
Bone Marrow Transplant, 21 (9), 873-8
PubMed 9613778

Publications 1996

Kolstad A, Holte H, Kvaløy S, Jakobsen E, Erikstein B, Aurlien E, Kvalheim G, Bøhler PJ, Langholm R (1996)
[High-dose therapy with autologous stem cell support in malignant lymphoma and breast cancer. Experiences with hematopoietic stem cells isolate from blood]
Tidsskr Nor Laegeforen, 116 (21), 2547-51
PubMed 8928122